Kiniksa Pharmaceuticals, Ltd. (KNSA) financial statements (2021 and earlier)

Company profile

Business Address CLARENDON HOUSE
HAMILTON, HM11
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments323233307
Cash and cash equivalents1144772
Short-term investments209186235
Restricted cash and investments0  
Other undisclosed current assets1086
Total current assets:333242314
Noncurrent Assets
Operating lease, right-of-use asset72
Property, plant and equipment466
Restricted cash and investments 00
Deferred costs  0
Deferred income tax assets04
Other noncurrent assets6  
Deferred tax assets, net1
Total noncurrent assets:16138
TOTAL ASSETS:349255322
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities302627
Accounts payable1611
Accrued liabilities292016
Debt 2 
Other liabilities000
Other undisclosed current liabilities2 15
Total current liabilities:322843
Noncurrent Liabilities
Long-term debt and lease obligation51 
Operating lease, liability51
Liabilities, other than long-term debt100
Accounts payable and accrued liabilities  0
Other liabilities10 
Total noncurrent liabilities:610
Total liabilities:382943
Stockholders' equity
Stockholders' equity attributable to parent, including:312225279
Additional paid in capital829581473
Accumulated other comprehensive income (loss)(0)0(0)
Accumulated deficit(517)(356)(194)
Other undisclosed stockholders' equity attributable to parent000
Total stockholders' equity:312225279
TOTAL LIABILITIES AND EQUITY:349255322

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Operating expenses(157)(170)(108)
Operating loss:(157)(170)(108)
Nonoperating income
(Investment Income, Nonoperating)
165
Loss from continuing operations before income taxes:(156)(164)(103)
Income tax expense (benefit)(5)20
Net loss available to common stockholders, diluted:(161)(162)(103)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(161)(162)(103)
Comprehensive loss:(161)(162)(103)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(161)(162)(103)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: